ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX - News) announced today that clinical data for retigabine from the Phase III RESTORE program will be presented at the 8th European Congress on Epileptology, which will be held at the Berlin Internationales Congress Centrum (ICC) in Berlin, Germany, September 21-24, 2008.
